International Journal of Cell Cloning, Vol 10, 190-195, Copyright © 1992 by AlphaMed Press
Differential lysis of tumor target cells displayed by lymphokine activated killer (LAK) cell clones
P Bean, R Agah and A Mazumder
Department of Pathology, University of Southern California, School of Medicine, Los Angeles.
Lymphokine-activated killer (LAK) cells exhibit major histocompatibility
complex (MHC) unrestricted cytolysis against a wide variety of fresh and
cultured tumor cells. Because previous work from our laboratory suggested
that trypsin treatment of unseparated populations of LAK cells had a
differential effect on lysis of different tumors, in this report we
analyzed the lytic specificity of LAK cell clones against a panel of three
different targets: MCA, B16 and YAC-1. We found that 21 out of the 24
analyzed murine spleen and bone marrow clones killed a combination of two,
but not all three, of these tumor cells. Determinations of the phenotype of
10 LAK cell clones showed six with rearrangements for the T cell receptor
(TCR) beta chain gene, suggesting a T cell origin, and four with germ line
configurations for the TCR beta and delta chain genes, a result consistent
with a non-T cell lineage. This cloning procedure provided an experimental
tool to develop new procedures of adaptive immunotherapy.
